Abstract
Chemical proteomics provides a powerful means to gain systems-level insight into the mode of action of small molecules and/or natural products. In contrast to high-throughput screening efforts which only interrogate selected subproteomes such as kinases and often only consider individual domains, the methodology presented herein allows for the determination of the molecular targets of small molecules or drugs in a more relevant physiological setting. As such, the compound of interest is exposed to the entire variety of cellular proteins considering all naturally occurring posttranslational modifications and activation states. Samples prepared according to the procedures described in this protocol are compatible with lysates from cultured cell lines, primary cells, or samples from biopsies. In combination with state-of-the-art mass spectrometry techniques this approach grants access to a comprehensive view of small molecule-target protein interactions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10(7):507–519
Schenone M, Dancik V, Wagner BK et al (2013) Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol 9(4):232–240
Sillaber C, Herrmann H, Bennett K et al (2009) Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest 39(12):1098–1109
Terstappen GC, Schlupen C, Raggiaschi R et al (2007) Target deconvolution strategies in drug discovery. Nat Rev Drug Discov 6(11):891–903
Brown EJ, Albers MW, Bum Shin T et al (1994) A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369(6483):756–758
Harding MW, Galat A, Uehling DE et al (1989) A receptor for the immuno-suppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 341(6244):758–760
Taunton J, Hassig CA, Schreiber SL (1996) A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272(5260):408–411
Ito T, Ando H, Suzuki T et al (2010) Identification of a primary target of thalidomide teratogenicity. Science 327(5971):1345–1350
Sun L, Wang H, Wang Z et al (2012) Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148(1–2):213–227
Huber KVM, Salah E, Radic B et al (2014) Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature 508(7495):222–227
Rix U, Superti-Furga G (2009) Target profiling of small molecules by chemical proteomics. Nat Chem Biol 5(9):616–624
Nomura DK, Dix MM, Cravatt BF (2010) Activity-based protein profiling for biochemical pathway discovery in cancer. Nat Rev Cancer 10(9):630–638
Savitski MM, Reinhard FBM, Franken H et al (2014) Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346(6205):1255784
Huber KVM, Olek KM, Müller AC et al (2015) Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling. Nat Meth 12(11):1055–1057
Schirle M, Bantscheff M, Kuster B (2012) Mass spectrometry-based proteomics in preclinical drug discovery. Chem Biol 19(1):72–84
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Huber, K.V.M., Superti-Furga, G. (2016). Profiling of Small Molecules by Chemical Proteomics. In: Reinders, J. (eds) Proteomics in Systems Biology. Methods in Molecular Biology, vol 1394. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3341-9_15
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3341-9_15
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3339-6
Online ISBN: 978-1-4939-3341-9
eBook Packages: Springer Protocols